A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma by Chang, Hye Jung et al.
ORIGINAL ARTICLE
korean j intern med 2011;26:403-409
http://dx.doi.org/10.3904/kjim.2011.26.4.403
pISSN 1226-3303    eISSN 2005-6648
http://www.kjim.or.kr
A Combination of Melphalan, Prednisone, and 50 mg 
Thalidomide Treatment in Non-Transplant-Candidate 
Patients with Newly Diagnosed Multiple Myeloma
Hye Jung Chang
1, Jae Hoon Lee
2, Young Rok Do
3, Sung-Hwa Bae
4, Jung-Lim Lee
5, Seung Hyun Nam
6,   
Sung-Soo Yoon
7, and Soo-Mee Bang
1 
Department of Internal Medicine, 1Seoul National University Bundang Hospital, Seongnam; 2Gachon University Gil Hospital, 
Incheon; 3Dongsan Medical Center, Keimyung University School of Medicine, Daegu; 4Catholic University of Daegu, Daegu; 
5Daegu Fatima Hospital, Daegu; 6Seoul Veterans Hospital, Seoul; 7Seoul National University Hospital, Seoul, Korea
Background/Aims: The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and 
thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-
line treatment. Because the side effects of thalidomide at a dose of ≥ 100 mg daily can be a barrier to effective treatment 
for these patients, we evaluated the efficacy and safety of a reduced dose of thalidomide, 50 mg, for non-transplant 
candidates.   
Methods: Twenty-one patients were treated in 4-week cycles, receiving 4 mg/m
2 melphalan and 40 mg/m
2 prednisone on 
days 1-7 and 50 mg thalidomide daily. The primary efficacy outcome was the overall response rate. Aspirin (100 mg daily) 
was also provided as prophylactic treatment for thromboembolism.
Results: The overall response rate was 57.1%; a complete response was seen in 23.8% of patients, a partial response 
in 33.3%, and stable disease in 9.5%. After a median follow-up time of 16.1 months, the median time to progression was 
11.4 months (95% confidence interval, 2.1 to 20.6); the median overall survival was not reached. Grades 3 and 4 adverse 
events included infection (10%), peripheral neuropathy (5%), diarrhea (5%), thrombosis (10%), and loss of consciousness 
(10%). Two patients discontinued treatment due to loss of consciousness and neuropathy.
Conclusions: Low-dose thalidomide (50 mg) plus melphalan and prednisone is an effective combination drug therapy 
option for newly diagnosed myeloma patients who are ineligible for high-dose chemotherapy.
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INTRODUCTION
Multiple myeloma accounts for approximately 10% of 
hematological malignancies and has increased in fre-
quency due to aging of the general population [1]. Half of 
all multiple myeloma patients are older than 70 years of 
age, and 20% are older than 80 years of age [2]. In Korea, 
the incidence of multiple myeloma has increase steadily 
over the last 25 years [3], and the current incidence rate 
exceeds 1.0/100,000. Aging is an important factor that 
has contributed to the increase in the incidence of multiple 
myeloma in Korea [4]. 
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Thalidomide has been successfully combined with 
corticosteroids and alkylating agents in the treatment 
of multiple myeloma. Palumbo et al. [5] showed that a 
combination of melphalan, prednisone, and thalidomide 
(MPT) showed a significant difference in progression-free 
survival compared with melphalan and prednisone alone 
(MP), but had no benefit for overall survival. Studies by 
the Intergroupe Francophone du Myelome (IFM), 01/01 
trial [6] and Wijermans et al. [7] showed similar results. 
The IFM 99-06 trial reported a significant overall survival 
advantage for MPT compared with MP treatment [8]. 
These results indicated that the MPT combination can be 
considered an effective first-line treatment for elderly pa-
tients with multiple myeloma.
The optimal dose of thalidomide in an MPT regimen 
has yet to be determined. In two previous studies, the dose 
of thalidomide was 100 mg daily [5,6], and another study 
used a dose of 200 mg daily [7]. In the IFM 99-06 study, 
patients received a median dose of 200 mg/day [8]. How-
ever, these doses resulted in numerous adverse effects. 
Although toxic effects of MPT such as thromboembolism 
are manageable (e.g., low-dose aspirin for the prophylaxis 
of deep venous thromboembolism), a reduction in the dose 
of thalidomide as soon as symptoms appear is recom-
mended. Thalidomide toxicity increases with the dose [9]. 
The side effects of thalidomide at a dose of ≥ 100 mg daily 
are barriers to effective treatment for patients who are 
not candidates for high-dose therapy as a first-line treat-
ment. Therefore, we evaluated the efficacy and safety of a 
reduced dose of thalidomide, 50 mg daily, in an MPT regi-
men for non-transplant candidates.
METHODS
Patients
The study enrolled patients from seven clinical centers 
in Korea. Patients were previously untreated myeloma pa-
tients who were between the ages of 18 and 85 years, had 
measurable disease, a monoclonal (M) protein concentra-
tion of ≥ 1 g/dL or a urine M protein concentration of ≥ 
400 mg/day, an expected survival time of ≥ 3 months, and 
a creatinine clearance rate of ≥ 20 mL/min. Exclusion cri-
teria were presence of another cancer, psychiatric disease, 
or any grade 2 peripheral neuropathy. Abnormal cardiac 
function, preexisting pulmonary embolism, and abnormal 
liver function were not criteria for exclusion. 
The study protocol was approved by the institutional re-
view boards of each participating center. All patients gave 
written informed consent before entering the study, which 
was performed in accordance with the Declaration of Hel-
sinki and the Korean Multiple Myeloma Working Party 
(KMMWP-KMM62). 
Study design
This study was an open-label, non-randomized, clinical 
trial conducted at seven hospitals in Korea. The primary 
efficacy outcome was the overall response rate (ORR), 
classified as a complete response (CR), very good partial 
response (VGPR), or a partial response (PR). Secondary 
outcomes included time to disease progression (TTP), 
overall survival (OS), and toxicity. TTP was defined as the 
time from initiation of treatment to disease progression; 
deaths resulting from causes other than disease progres-
sion were censored. OS was defined as the time interval 
from initiation of treatment to death from any cause. 
Duration of response was defined as the period from the 
first observation of a PR to the date of disease progression; 
deaths resulting from causes other than progression were 
censored. 
Treatment and dose modification
Treatment consisted of 4-week cycles of melphalan (4 
mg/m
2) and prednisone (40 mg/m
2) on days 1-7, with 50 
mg thalidomide given daily. Patients were also given 100 
mg aspirin daily to prevent deep vein thromboembolism. 
Dose reduction of MPT was allowed after the first 4-week 
cycle. Treatment continued for six cycles or more, at the 
investigator’s discretion, until disease progression, with-
drawal of consent, or unacceptable treatment-related 
toxicity occurred. Melphalan and thalidomide could be 
withheld during cycle 1 for reasons of neutropenia or 
thrombocytopenia higher than grade 3. Patients with de-
layed recovery of hematologic toxicity (i.e., grade > 1 for 
more than 2 weeks) had a 25% dose reduction of melpha-
lan. 
Assessment of response and toxicity
Patient response was assessed using serum and urine 
M protein concentrations measured after cycle 2 and af-
ter every other cycle thereafter. Response to treatment, 
determined at the time of maximal response, was defined chang HJ, et al. MPT50 for MM in non-transplant candidates    405
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according to the European Group for Blood and Marrow 
Transplantation criteria [9]. Additional categories of near-
complete response (nCR), defined by the absence of M pro-
tein after electrophoresis with positive immunofixation, 
and VGPR, defined by a > 90% reduction in M protein, 
were included. CR required confirmed disappearance of M 
protein in the serum and urine by immunofixation studies 
and < 5% plasma cells upon bone marrow examination. A 
PR was defined as a ≥ 50% reduction in serum M protein 
and a reduction in 24-hour urine M protein of ≥ 90% or to 
< 200 mg, plus no increase in the number or size of lytic 
bone lesions or any other evidence of disease progression. 
Progressive disease (PD) was defined as recurrence of dis-
ease after a CR or a > 25% increase in M protein from its 
lowest point. Patients who did not meet the criteria for CR, 
PR, or PD were classified as having stable disease. Adverse 
events were assessed during each cycle and graded ac-
cording to the National Cancer Institute Common Toxicity 
Criteria, version 3.0 (NCI-CTC v3.0). 
Statistical analysis
This study was initially planned using a grouped se-
quential design [10] with an expected risk reduction (RR) 
of 70% in the MPT arm compared with a 50% RR in the 
MP arm (refer to Appendix 1). However, after the first 
stage, investigators decided to terminate the study early 
for two reasons: lack of insurance coverage for thalido-
mide and delayed enrollment. All statistical analyses were 
performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, 
USA). OS and TTP were estimated using the Kaplan-Meier 
method.
RESULTS
Patient characteristics
Twenty-one patients with newly diagnosed multiple my-
eloma, who were non-transplant candidates, were enrolled 
in our study between June 2006 and December 2008. 
Clinical characteristics of the cohort are summarized 
in Table 1. In brief, the median patient age was 70 years 
(range, 59 to 79), with three patients (14.3%) older than 75 
years, and 47.6% of the patients were men. Six (28.6%) and 
15 (71.4%) patients were classified as Durie-Salmon stages 
II and III, respectively. 
Response
A total of 21 patients received 92 cycles of MPT (me-
dian, 4 cycles; range, 1 to 12) (Table 2). Responses of three 
patients could not be evaluated because of death or loss 
Table 1. Patient characteristics (n = 21)
characteristics No. of patients (%)
Sex (male:female) 10:11 (47.6:52.4)
Age, yr
median 70
Range 59-79
Performance status
ECOG 0-1  13 (61.9)
ECOG 2 8 (38.1)
durie-Salmon stage at diagnosis
IIA/B 5/1 (23.8/4.8)
IIIA/B 13/2 (61.9/9.5)
Paraprotein type
IgG/IgA/IgD    7/8/1 (33.3/38.1/4.8)
Light chain (κ/λ) 2/2 (9.5/9.5)
Plasmacytosis in bone marrow, %
median 43.3
Range 4.6-86.2
Hemoglobin, g/dL
median 9.1
Range    4.0-13.2
Albumin, g/dL
median 3.5
Range   4.0-13.2
β2-microglobulin, g/dL
median 7.4
Range   1.7-23.1
Bone related event at diagnosis 7 (33.3)
ECOG, Eastern Cooperative Oncology Group score.
Table 2. Response rates of patients after a combina-
tion of melphalan, prednisone, and thalidomide thera-
py (n = 21)
Response No. of patients (%)
complete response   5 (23.8)
Partial response   7 (33.3)
Stable disease 2 (9.5)
Progressive disease  4 (19.1)
Not available  3 (14.3)406    The Korean Journal of Internal Medicine Vol. 26, No. 4, december 2011
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to follow-up within two cycles of MPT therapy. Among 
18 patients available for evaluation, five patients (23.8%) 
achieved a CR after two cycles of therapy, including two 
patients with an nCR, and six patients (33.3%) had a PR, 
including one patient with a VGPR, resulting in an ORR of 
57.1%. The median duration of response was 5.5 months 
(range, 0.7 to 17.5).
Survival
The median duration of follow-up was 16.1 months 
(range, 2.1 to 42.5). The median TTP was 11.4 months (95% 
confidence interval, 2.1 to 20.6); the median OS was not 
reached (Fig. 1). 
Toxicities
Twenty patients were assessed for toxicity from MPT. 
Hematologic and non-hematologic toxicities are shown 
in Table 3. Grades 3 and 4 hematologic toxicities in-
cluded neutropenia (5%), thrombocytopenia (5%), and 
anemia (5%). Grades 3 and 4 non-hematologic toxicities 
were thromboembolism (10%), infection (10%), loss of 
consciousness (10%), and diarrhea (5%). Peripheral neu-
ropathy was noted in 50% of patients, including 5% with 
grade 3 neuropathy. Fatigue, nausea, and hepatotoxicity of 
grades 1 and 2 were also reported during MPT therapy. 
One patient (4.8%) died of an unknown cause after she 
had received one cycle of MPT. No autopsy was performed. 
One patient experienced loss of consciousness after he had 
received one cycle of chemotherapy. No specific abnormal-
ities were found in this patient upon brain imaging, but it 
was decided that he would discontinue the MPT regimen. 
Another patient had grade 3 sensory neuropathy after he 
had been treated with four cycles of MPT. He achieved CR, 
and it was decided that he would discontinue MPT, as he 
did not want maintenance therapy.
DISCUSSION
High-dose chemotherapy (HDT) followed by autologous 
stem cell transplantation (ASCT) has improved the sur-
vival of both young [10] and elderly patients with multiple 
myeloma [11]. However, about half of patients with newly 
diagnosed multiple myeloma are over 70 years of age or 
have inadequate end-organ function, which are potential 
limitations for treatment with HDT and ASCT. The com-
bination of melphalan and prednisone has been the stan-
dard treatment for such patients, but patient outcomes are 
less than satisfactory [12]. 
Recently, thalidomide used in combination with MP has 
become a first-line treatment regimen in non-transplant 
candidates and has resulted in superior outcomes in el-
derly patients compared with MP treatment alone [5-8]. 
Although MPT has shown promising results, the optimal 
dose of thalidomide has yet to be established. The Nordic 
group suggested that increasing the dose of thalidomide 
to 400 mg/day in very elderly patients could be associ-
ated with greater toxicity and more adverse outcomes [13]. 
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Figure 1. (A) Time to progression and (B) overall survival.
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Therefore, to reduce the adverse effects associated with 
thalidomide, the dose of thalidomide was decreased from 
800 mg in the first trial to 100 mg, and more recently, to 
50 mg/day [14-16]. The goal of clinicians is to use as low a 
dose of thalidomide as possible. 
This study used 50 mg thalidomide plus MP and dem-
onstrated a 57.1% ORR. In comparison, the IFM 01/01 
trial, which included patients older than 75 years, showed 
a 62% ORR after MPT treatment [6]. Complete and partial 
response rates were 23.8% and 33.3% in this study and 7% 
and 41% in the IFM 01/01 trial, respectively. The median 
progression-free survival (PFS) time was 24.1 months in 
the IFM 01/01 trial, and the median time to progression 
was 11.4 months in this study. Our study showed similar 
response rates but shorter response durations than did 
the IFM 01/01 trial. The use of novel agents (thalidomide, 
bortezomib, lenalidomide) is also associated with high 
response rates, and recent trials showed that patients 
achieving CR had significantly longer PFS than patients 
achieving PR [17]. Although our study demonstrated a 
higher CR rate than the IFM 01/01 trial reported, the du-
ration of response and survival were less satisfactory for 
our cohort. However, our definition of CR was different 
from that of the IFM 01/01 trial, as we included nCR pa-
tients, whereas the IFM 01/01 trial did not. Additionally, 
patients in the IFM 01/01 trial were treated for 12 cycles, 
whereas our patients were typically treated for six cycles. 
These differences might explain the apparent discrepancy 
between the studies in CR rate and survival. 
With respect to the withdrawal rate from the IFM 01/01 
trial, 48 patients (42.4%) discontinued treatment due 
to toxicities, whereas two patients (10%) discontinued 
treatment in our study. Additionally, the IFM 01/01 trial 
reported that 20% of patients required a dose reduction of 
thalidomide to 50 mg/day due to grades 1 and 2 peripheral 
neuropathy. Waage et al. [13] had similar results for a pa-
tient who was not eligible for HDT with ASCT. They dem-
onstrated a 57% ORR and a median of 15 months PFS with 
MP and 200 or 400 mg of thalidomide. Fifty-nine patients 
(32.4%) discontinued thalidomide treatment due to toxici-
ty. These data suggest that patients with multiple myeloma 
treated with 50 mg thalidomide had good compliance.
Venous thromboembolism (VTE) is a critical clinical 
condition manifesting as deep vein thrombosis and/or 
pulmonary embolism. Thalidomide treatment is associ-
ated with an increased risk of VTE, especially when used 
in combination with dexamethasone and/or chemother-
apy. The risk is generally greatest in patients treated with 
thalidomide as a first-line therapy, as opposed to patients 
treated after relapse [18]. The percentage of thromboem-
bolic events with thalidomide therapy in our study (10%) 
was higher than previously reported in Korean patients 
in general (3.9%) [19]. However, this incidence was lower 
than data from Western cohorts, which showed 6-17% 
incidences of VTE [5,6,8] after MPT treatment. Our study 
cohort included just 21 patients, which may have affected 
Table 3. Adverse toxicity events after a combination of melphalan, prednisone, and thalidomide treatment
Grade 1/2  Grade 3/4 
Hematologic toxicity
 (per cycle, n = 20)
Neutropenia 13 (65.0) 1 (5.0)
Anemia 19 (95.0) 1 (5.0)
Thrombocytopenia   6 (30.0) 1 (5.0)
Non-hematologic toxicity
 (per patient, n = 20)
Neuropathy   9 (45.0) 1 (5.0)
Thromboembolism 1 (5.0)   2 (10.0)
Nausea   2 (10.0) 0 (0.0)
diarrhea 0 (0.0) 1 (5.0)
Infection 0 (0.0)   2 (10.0)
Fatigue 1 (5.0) 0 (0.0)
Hepatotoxicity   2 (10.0) 0 (0.0)
Loss of consciousness  0 (0.0)   2 (10.0)
Values are presented as number (%).408    The Korean Journal of Internal Medicine Vol. 26, No. 4, december 2011
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our interpretation of side effects.
The small number of patients enrolled in our study is a 
major limitation of this study. Despite the original study 
design, we decided to terminate this trial early for two 
reasons: absence of adequate insurance coverage of tha-
lidomide and delayed enrollment of patients. Thalidomide 
is not covered by insurance for use as a first-line chemo-
therapy drug in Korea, but only as a secondary treatment 
after progression with first-line chemotherapy. Further-
more, patients with newly diagnosed multiple myeloma 
who were first treated with MP plus 50 mg thalidomide 
(MPT50) in our study, at high personal cost, could not use 
thalidomide combination therapy as a second-line chemo-
therapy option due to lack of insurance coverage. These 
challenges also resulted in delayed patient enrollment. 
Additionally, the availability of other new, active drugs 
(i.e., bortezomib and lenalidomide), which elicited good 
responses from patients not eligible for transplant [20,21], 
delayed enrollment of a sufficient number of patients. We 
evaluated the responses of 20 patients, 12 of whom re-
sponded to MPT50. According to the algorithm for enroll-
ment (Appendix 1), our ideal cohort should have been 40 
patients. Due to the various factors that prevented enroll-
ment of a sufficient number of patients in a timely fashion, 
we decided to end this trial early.
In conclusion, our results suggest that MPT50 is an 
effective first-line treatment option for non-transplant-
eligible patients with multiple myeloma, including elderly 
patients. To better identify the most appropriate patients 
for MPT50 therapy, however, additional large-scale pro-
spective studies are needed.
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